Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Microparticles for inhalational delivery of antipseudomonal antibiotics.

Tsifansky MD, Yeo Y, Evgenov OV, Bellas E, Benjamin J, Kohane DS.

AAPS J. 2008 Jun;10(2):254-60. doi: 10.1208/s12248-008-9033-8. Epub 2008 May 3.

2.

Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis.

Yang Y, Tsifansky MD, Wu CJ, Yang HI, Schmidt G, Yeo Y.

Pharm Res. 2010 Jan;27(1):151-60. doi: 10.1007/s11095-009-9991-2. Epub 2009 Oct 22.

PMID:
19847626
3.

Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.

Adi H, Young PM, Chan HK, Agus H, Traini D.

Eur J Pharm Sci. 2010 Jun 14;40(3):239-47. doi: 10.1016/j.ejps.2010.03.020. Epub 2010 Apr 3.

PMID:
20371286
4.

Controlled release antibiotics for dry powder lung delivery.

Adi H, Young PM, Chan HK, Salama R, Traini D.

Drug Dev Ind Pharm. 2010 Jan;36(1):119-26. doi: 10.3109/03639040903099769.

PMID:
19656005
5.

Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model.

Yang Y, Tsifansky MD, Shin S, Lin Q, Yeo Y.

Biotechnol Bioeng. 2011 Jun;108(6):1441-9. doi: 10.1002/bit.23046. Epub 2011 Jan 15.

PMID:
21488050
6.

Cospray dried antibiotics for dry powder lung delivery.

Adi H, Young PM, Chan HK, Stewart P, Agus H, Traini D.

J Pharm Sci. 2008 Aug;97(8):3356-66.

PMID:
17990305
7.

Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa.

Lu Q, Yang J, Liu Z, Gutierrez C, Aymard G, Rouby JJ; Nebulized Antibiotics Study Group.

Am J Respir Crit Care Med. 2011 Jul 1;184(1):106-15. doi: 10.1164/rccm.201011-1894OC. Epub 2011 Apr 7.

PMID:
21474643
8.

Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.

Antonela Antoniu S.

Expert Rev Anti Infect Ther. 2012 Dec;10(12):1439-46. doi: 10.1586/eri.12.136. Review.

PMID:
23253321
9.
10.

Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.

Cantón R, Cobos N, de Gracia J, Baquero F, Honorato J, Gartner S, Alvarez A, Salcedo A, Oliver A, García-Quetglas E; Spanish Consensus Group for Antimicrobial Therapy in the Cystic Fibrosis Patient.

Clin Microbiol Infect. 2005 Sep;11(9):690-703. Review.

11.

Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa.

Ferrari F, Lu Q, Girardi C, Petitjean O, Marquette CH, Wallet F, Rouby JJ; Experimental ICU Study Group.

Intensive Care Med. 2009 Oct;35(10):1792-800. doi: 10.1007/s00134-009-1605-2. Epub 2009 Aug 4.

PMID:
19652947
12.

Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.

Church DA, Kanga JF, Kuhn RJ, Rubio TT, Spohn WA, Stevens JC, Painter BG, Thurberg BE, Haverstock DC, Perroncel RY, Echols RM.

Pediatr Infect Dis J. 1997 Jan;16(1):97-105; discussion 123-6.

PMID:
9002118
13.
14.

The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?

Banerjee D, Stableforth D.

Drugs. 2000 Nov;60(5):1053-64. Review.

PMID:
11129122
15.

Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery.

Sweeney LG, Wang Z, Loebenberg R, Wong JP, Lange CF, Finlay WH.

Int J Pharm. 2005 Nov 23;305(1-2):180-5. Epub 2005 Oct 19.

PMID:
16242277
16.

Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model.

Zelenitsky SA, Karlowsky JA, Hoban DJ, Kabani A, Zhanel GG.

Chemotherapy. 1998 Jan-Feb;44(1):1-6.

PMID:
9444401
18.

Spray dried inhalable ciprofloxacin powder with improved aerosolisation and antimicrobial activity.

Osman R, Kan PL, Awad G, Mortada N, El-Shamy AE, Alpar O.

Int J Pharm. 2013 Jun 5;449(1-2):44-58. doi: 10.1016/j.ijpharm.2013.04.009. Epub 2013 Apr 12.

PMID:
23587967
19.

Steroid-decorated antibiotic microparticles for inhaled anti-infective therapy.

Lee SH, Teo J, Heng D, Zhao Y, Ng WK, Chan HK, Tan RB.

J Pharm Sci. 2014 Apr;103(4):1115-25. doi: 10.1002/jps.23874. Epub 2014 Feb 7.

PMID:
24510431
20.

Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.

Geller DE, Weers J, Heuerding S.

J Aerosol Med Pulm Drug Deliv. 2011 Aug;24(4):175-82. doi: 10.1089/jamp.2010.0855. Epub 2011 Mar 11. Review.

Items per page

Supplemental Content

Write to the Help Desk